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a  b s  t  r a  c t
Heparin is a natural agent with antithrombotic action, commercially available for thera-
peutic  use as  unfractionated heparin and low  molecular weight heparin. Heparin-induced
thrombocytopenia (HIT) is a serious adverse reaction to heparin that promotes antibody-
mediated  platelet activation. HIT is deﬁned as a relative reduction in platelet count of 50%
(even  when the platelet count at  its  lowest level is above > 150 x  109/L) occurring within ﬁve
to  14  days after initiation of the therapy. Thrombocytopenia is the main feature that directs
the  clinical suspicion of the  reaction and the  increased risk of thromboembolic complica-
tions  is the  most important and paradoxical consequence. The diagnosis is a  delicate issue,
and requires a combination of clinical probability and laboratory tests for the detection of
platelet activation induced by HIT antibodies. The absolute risk of HIT has been estimated
between  1% and 5% under treatment with unfractionated heparin, and less than 1% with
low  molecular weight heparin. However, high-quality evidence about the risk of HIT from
randomized  clinical trials is scarce. In addition, information on the frequency of  HIT in
developing  countries is not widely available. This review aims to provide a better under-
standing  of the  key features of this reaction and updated information on its frequency to
health  professionals and other interested parties. Knowledge, familiarity, and access to ther-
apeutic options for the treatment of this adverse reaction are  mandatory to minimize the
associated  risks, improving patient safety.
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r  e  s u  m o
A  heparina é  um agente natural com ac¸ão  antitrombótica, sendo disponibilizadas para uso
terapêutico  a  heparina não fracionada e a  heparina de baixo peso molecular. A tromboci-
topenia  induzida por heparina (TIH) é  uma reac¸ão  adversa grave às  heparinas mediada por
anticorpos que promovem ativac¸ão  de plaquetas. A TIH é deﬁnida como uma reduc¸ão  rela-
tiva  na contagem de  plaquetas de 50% (mesmo se a contagem de plaquetas no seu nível mais
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baixo estiver acima 150 x  109/L) que pode ocorrer no período de cinco a  14  dias após o início
da terapia com o medicamento. A  trombocitopenia é a principal característica que direciona
a suspeita clínica da reac¸ão,  sendo o  aumento do risco de  complicac¸ões  tromboembólicas a
consequência mais importante e  paradoxal. O  diagnóstico é  uma  questão delicada e  requer
a combinac¸ão  da probabilidade clínica com testes laboratoriais para detectar a  ativac¸ão  pla-
quetária induzida pelos anticorpos da TIH. O risco absoluto de TIH tem sido estimado entre 1
e  5% no tratamento com heparina não fracionada e inferior a 1% no uso de  heparina de baixo
peso molecular. No entanto, evidências de alta qualidade provenientes de ensaios clínicos
randomizados sobre a  frequência dessa reac¸ão  são escassas. Além disso, informac¸ões  sobre
a frequência de  TIH em países em desenvolvimento não são amplamente disponíveis. Esta
revisão teve como objetivo fornecer aos proﬁssionais de saúde e demais interessados um
melhor conhecimento sobre a  TIH e as principais características dessa reac¸ão,  bem como
apresentar dados atualizados sobre a  frequência da mesma. Conhecimento, familiaridade e
acesso a  opc¸ões  terapêuticas para o tratamento dessa reac¸ão  adversa são necessários para
minimizar os riscos associados, melhorando a  seguranc¸a  do paciente.
Introduction
Heparin is one of the  most commonly used medications world-
wide,  with over one trillion units used in the United States
yearly.1 It is an anticoagulant that occurs naturally in  the
organism  in small amounts, and whose activity is  expressed
through  ligation to  a  plasma cofactor, the antithrombin, thus
inactivating  thrombin (factor IIa) and factors Xa, IXa, and Xia.2
For medicinal purposes, the drug is  extracted from animal
mucosa  (swine or bovine), and used mainly in the treatment
and  prophylaxis of thromboembolic disorders.
There are two types of heparin drugs available: unfrac-
tionated heparin (UFH), also called standard heparin; and
low-molecular-weight heparin (LMWH). UFH is  a  heteroge-
neous  mixture of glycosaminoglycans with molecular weight
ranging  from 3,000 to 30,000 on average. LMWH  is  obtained
by  fractionation or  depolymerization of standard heparin
yielding fragments, with mean molecular weight ranging
from  4,500 to 5,000.2,3 Therefore, LMWH  constitutes a group
of  several drugs (e.g. enoxaparin, dalteparin, nadroparin,
tinzaparin, etc.) differing in some extent in their pharma-
cokinetic properties and anticoagulant proﬁle, since they
are  prepared by different methods of depolymerization.
LMWH presents a  more  predictable dose-response relation-
ship  and an improved bioavailability after subcutaneous
administration due to reduced binding to plasma proteins,
macrophages, and endothelial cells, thus allowing for a ﬁxed-
dose  regime.2,4
Among the possible adverse effects during treatment with
heparin,  hemorrhage is the main and best-known risk, occur-
ring  in  5% to 10%  of exposed patients.3 Another important
adverse drug reaction faced by clinicians during treatment
with  heparin is  heparin-induced thrombocytopenia (HIT),
potentially the most morbid complication of heparin ther-
apy.  Formerly termed white clot syndrome or HIT type II,
HIT  is a  type of acquired hypercoagulability syndrome caused
by  an immune-mediated reaction induced by the heparin
compound, and commonly followed by venous or arterial
thrombosis.5–7 The ﬁrst report of the association of HIT with
thrombosis dates from 1958; since then, there has been a mas-
sive  effort to explain this intriguing syndrome.
Purpose  of  the  review
Considering the potential consequences of a thrombotic
event, HIT is an important and life-threatening adverse drug
reaction  following treatment with heparin. Therefore, this
study  aimed to review the literature addressing key character-
istics  of this syndrome, its frequency, and diagnostic issues,
in  order to aid HIT recognition in  daily clinical practice.
Pathophysiology  of  heparin-induced
thrombocytopenia
The pathophysiology of the thrombocytopenia in HIT  is still
not  completely understood.8 According to  the elucidated
mechanism, following the administration of heparin, platelet
factor  4 (PF4), a  small peptide stored in platelet -granules, is
released  in blood circulation due to a  transient and unspeciﬁc
platelet aggregation induced by direct interaction of platelets
with  heparin.9 Subsequently, heparin binds to PF4 due to
charge  differences, thus resulting in a macromolecular com-
plex  (PF4/heparin). The formation of this complex induces a
conformational change in  the molecules, resulting in the for-
mation  of several neo-epitopes.2,10,11 An  immune response
against these antigenic epitopes results in the production of
IgG,  IgM, and IgA antibodies.
The  clinical importance of IgA and IgM antibodies remains
uncertain, as they appear unable to cause platelet activa-
tion  in the presence of heparin,12,13 although in a  few HIT
cases  (<  10%), only IgA or IgM antibodies to  PF4/heparin are
detectable.11 The IgG antibodies react with the PF4/heparin
complex, forming an immunocomplex of PF4/heparin/IgG
antibodies (HIT antibodies), which has  the ability to bind to
platelets’  surfaces through their FcyRIIa receptor, inducing
platelet activation and aggregation.14,15 The intensive platelet
activation induced by HIT antibodies increases thrombin gen-
eration,  thus determining a hypercoagulability state.16,17
Observational data regarding the prevalence of HIT in  the
setting  of local or  systemic inﬂammation have also raised
the  possibility that additional cell types are involved in
the  pathogenesis of thrombosis, including leukocyte-platelet
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aggregates and monocytes.8,18 HIT antibodies can bind to
monocytes,  prompting their degranulation and the release of
several  procoagulant and inﬂammatory substances.19 More-
over,  there is  evidence that activated monocytes express tissue
factor  on their surface, which reinforces the  activation of
the  coagulation pathway.6 The activated coagulation system
also  determines the release of vesicular platelet-membrane
(platelet microparticles), which contains substances (GPIb,
GPIIb,  and GPIIIa, P-selectin, and thrombospondin) capable
of  increasing thrombin generation in vivo.10,20,21 In addition,
endothelial damage certainly plays a  role in HIT pathogen-
esis,  since it can be caused by immunoglobulins, cytokines
released by activated leukocytes, microparticles from acti-
vated  platelets, adhesion molecules from both activated
platelets and leukocytes, as  well as  by mechanical disrup-
tion  due to  surgical processes or pathological processes such
as  atherosclerosis.6 Recently, in the  setting of cardiothoracic
patients, one study reported that HIT patients have posi-
tive  antibodies to Adamts-13 and a reduced concentration
of Adamts-13, which could be a  complicating factor in HIT
pathogenesis.22 Considering that patients needing antithrom-
botic  therapy with heparin may be bedridden at least to some
extent,  the procoagulant state, together with vascular injury
and  stasis, may  be a central mechanism of the venous and
arterial  thrombosis associated with the development of HIT.
It  has been shown that there is dissociation between
the development of HIT antibodies and the risk of HIT
occurrence.23 Therefore, not all patients who form HIT anti-
bodies  will develop thrombocytopenia or other sequelae of
HIT.7,24 The reticuloendothelial system may clear platelets
coated with antibodies from circulation, thus preventing the
clinical  manifestation of HIT in  most patients.19 However, the
reason  why some patients develop antibodies with the ability
to  activate platelets (functional antibodies) and others do not
is  currently unknown.25
Deﬁnitions  and  fundamental  characteristics
of heparin-induced  thrombocytopenia
HIT is  deﬁned as a relative reduction in platelet count of
50%  (even when the  count of platelets at its lowest level is
above  > 150 x 109/L) occurring within ﬁve to 14 days after
starting heparin therapy.26 Remarkably, HIT differs from a
non-immune heparin-associated thrombocytopenia (HAT),
which  is secondary to  a direct interaction of heparin with
platelets  and resolves spontaneously.10
The time pattern of HIT may  be difﬁcult to recognize
in the postoperative setting since platelet counts commonly
decrease after a  surgical procedure.26 Therefore, in postop-
erative patients, thrombocytopenia in HIT may be deﬁned
as  a  drop in  platelet counts of 50% or more  from the maxi-
mum  number of platelets, occurring after surgery and within
the  predeﬁned time frame.27 Noticeably, patients recently
exposed to heparin may  have circulating antibodies, and then
they  can develop rapid-onset HIT within 24 hours after a  new
heparin  administration.13 Delayed-onset HIT, when the syn-
drome  occurs months after the  discontinuation of heparin,
has  also been described.28,29 Delayed-onset HIT is typically
recognised because of a  thrombotic event; the possibility of an
unsuccessful long-term anticoagulant therapy is  a challenge
to  the diagnosis of the  syndrome.12
Clinical suspicion of this adverse drug reaction mainly
occurs because of thrombocytopenia, which is  the central fea-
ture of the syndrome. However, the  clinical suspicion must
be  conﬁrmed by the demonstration of antibodies with ability
to  induce platelet activation.26 Thrombotic events may  also
prompt  a  suspicion of HIT, since these complications can occur
in  an  unpredictable manner throughout the use of the drug,
and  even before thrombocytopenia status is reached.7,30
Diagnosis  and  treatment  of  heparin-induced
thrombocytopenia
The diagnosis of HIT is a  challenging issue. It requires the
combination of clinical likelihood and laboratory tests to
detect  platelet activation induced by HIT antibodies.31,32 Some
assays,  known as  functional assays, are able to demonstrate
the presence of clinically relevant antibodies.33 These assays
are  the  C-serotonin released assay (SRA)14 and the heparin-
induced  platelet activation assay (HIPA), which also present
the  most favourable sensitivity/speciﬁcity trade-off.33,34
The platelet aggregation assay has also been used, but lacks
adequate  sensitivity and is not generally recommended.35
Another available procedure is  detection of HIT antibodies in
the patient’s sera through immunoassays. There are a  number
of  commercial enzyme-linked immunoassays (ELISA) avail-
able  to diagnose HIT. They are able to detect pathogenic and
non-pathogenic antibodies, and commonly lead to a high
rate  of false-positives.33 However, despite their low speciﬁcity,
these  assays represent an  ideal test to rule out HIT; their com-
bination  with a  functional assay can be a  valuable procedure
to  screen negative cases. Thus, functional assays should be
reserved  to  just a small numbers of cases.
A clinical scoring system aiming to improve the
clinical diagnosis of HIT has been developed.32 Using
four clinical features of HIT (magnitude of thrombocytopenia,
timing of thrombocytopenia regarding heparin exposure,
occurrence of thrombosis or other sequelae, and absence of
other  explanations for the thrombocytopenia), the 4Ts sco-
ring  system is  a  risk assessment tool that classiﬁes patients
within  low, moderate, and high probabilities for HIT. Several
studies  have investigated the usefulness of combining the
4Ts  scoring system and laboratory testing in the diagnosis of
HIT.36,37 However, this method may  lack satisfactory ability
to  identify the probability of HIT in order to  be widely used in
clinical  practice.38,39
Considering the role of thrombin generation in HIT patho-
genesis,  all sources of heparin should be suspended when
the  reaction occurs. In case of a  strong suspicion, the results
of  the assays should not even be  waited for.40 However, the
cost-beneﬁt of introducing a  treatment with an  alternative
anticoagulant must be  considered in  the  clinical decision-
process, due to  signiﬁcant risk of bleeding.34 There is  a
rationale for the use of direct thrombin inhibitors (argatroban,
lepirudin, or bivalirudin) and of an agent anti-factor Xa (fon-
daparinux)  that inhibits thrombin generation to treat HIT.
Treatment  must continue until platelet count becomes nor-
mal,  and asymptomatic thrombosis should be investigated.
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In cases of HIT complicated by thromboembolic events, ther-
apy  with alternative anticoagulants must be carefully followed
by  therapy with warfarin for two or three months.35 An
evidence-based guideline regarding the management of HIT
is  available.19
Some procedures should be avoided in the management
of HIT. LMWH  is not a  therapeutic option, since it cross-
reacts with circulating HIT antibodies.31,40 Oral anticoagulant
drugs must also not be used because they reduce protein C
and  S levels, thus contributing to an increase in  thrombin
generation and resulting in a  higher risk of thromboem-
bolic complications.32 Indeed, venous gangrene has developed
in  patients treated for HIT with oral anticoagulants. There-
fore,  warfarin therapy may  be carefully started only after the
platelet  count becomes normal. Platelet transfusion should
not  be  performed, as it  might induce or exacerbate throm-
boembolic complications.40
Frequency  of  heparin-induced
thrombocytopenia
HIT may  develop following any mode of heparin
administration,10,34 including parenteral infusions,28 subcu-
taneous therapy,41 and even due to low-grade exposures such
as  heparin line ﬂushes or following the insertion of heparin-
bonded  pulmonary artery catheters.42 The development of
HIT  is inﬂuenced by the type of heparin used (UFH or LMWH)
and  the type of heparin-exposed patient population.34 Also,
the  incidence of HIT appears to be higher with the  use of
bovine  heparin when compared with swine heparin. However,
data  regarding accurate values of the  incidence of HIT are
conﬂicting.34 Overall, it has been generally accepted that the
absolute  risk of HIT during treatment with UFH is between
1%  to 5%, and between 0.1% to 1% with LMWH.19,26,43 The
association of HIT with the type of heparin may  be justiﬁed
by  the higher molecular weight and degree of sulphation of
the  UFH, which determine a  higher probability to induce the
formation  of HIT antibodies when compared to the LMWH.
The  highest risk population comprises postoperative
patients receiving UFH (estimated incidence between 1% to
5%).34 Postoperative patients receiving LMWH  show a  lower
risk  of HIT (estimated incidence between 0.1% to 1%), together
with  medical and obstetrical patients exposed to UFH.41
In other settings, such as  medical and obstetrical patients
exposed only to LMWH  or receiving catheter ﬂushes with UFH,
HIT  is  described as  a rare event, with an incidence < 0.1%,34
although higher frequencies have been observed.44 Speciﬁc
characteristics of patients submitted to  certain surgeries were
also  shown to inﬂuence the risk proﬁle of HIT;18,23 however,
most studies have enrolled patients after orthopedic surgery.
Recent  investigations presented weak evidence suppor-
ting  the generally accepted incidence of HIT. Although a
lower  incidence of HIT in postoperative patients under throm-
boprophylaxis with LMWH  when compared with UFH was
shown,  randomized clinical trials that include HIT as an
outcome  are  scarce.45 Of note, in  a  recently published sys-
tematic  review, the absolute risk (incidence) of HIT in patients
subjected to major surgeries was  found to be similar for
both  types of heparins (incidence > 1% and < 10%) .45 These
ﬁndings are preliminary, but may  possibly impact clinical rec-
ommendations regarding platelet count monitoring during
thromboprophylaxis with heparin.
Special concern should be addressed regarding the  fre-
quency of HIT in Brazil. To the authors’ knowledge, there is  no
available information about the incidence of HIT in Brazil or
in  Latin America, and little information is available about the
frequency  of HIT in other developing countries. This is a con-
cern,  since the speciﬁcities in the population composition and
its  genetics can clearly inﬂuence the effects of drugs.46 Most
importantly, bovine heparin has shown a higher potential to
induce HIT when compared with swine heparin. While most
countries  do not produce this kind of heparin anymore, 40%
of  the manufactured products containing heparin in Brazil are
derived from a  bovine source.47 Therefore, there is a need for
an  improvement of knowledge and awareness regarding the
occurrence  of this adverse drug reaction in the clinical practice
of  Brazil. The poorly understood picture of HIT in  this country
may  contribute to a delayed recognition of the syndrome, thus
negatively  impacting morbidity and mortality of patients.
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